Co-Diagnostics, a molecular diagnostics firm, announced its submission of a 510(k) premarket notification to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro® platform. This test, developed during the pandemic, is pending FDA clearance and aims to expand PCR diagnostic access globally. The company is preparing for a potential U.S. launch while pursuing international regulatory approvals. Their Chief Commercialization Officer also recently discussed medical device innovation and AI impacts at a Salt Lake City industry event.
Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chron...
dLocal offers a unified payment gateway enabling global merchants to access over 60 emerging markets, fueling strong transaction volume and revenue growth. Although its take-rate has compressed to 0.71%, this is mainly due to merchant mix, volume tie...
Qualcomm introduced its Snapdragon 8 Elite Gen 6 chipsets, designed for high-end Android smartphones with enhanced on-device AI capabilities. Built using TSMC's 2-nanometer process, these chips target premium brands like Motorola, Xiaomi, and ZTE ami...
Simmons First National Corporation announced it will host an Investor Day on December 10, 2026, in New York City. The event will feature presentations by CEO Jay Brogdon, CFO Daniel Hobbs, and other executives discussing the company's strategic prior...
Quest Diagnostics announced it will release its third quarter 2026 financial results on October 22, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss the results, accessible via phone and webc...
